Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAN versus CEPTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAN versus CEPTAZ.
CEFOTAN vs CEPTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and causing cell lysis.
1-2 g IV/IM every 12 hours for 5-10 days; up to 6 g/day for severe infections.
1 to 2 g intravenously every 8 to 12 hours; maximum 6 g per day.
None Documented
None Documented
Terminal elimination half-life: 4.5 hours (intravenous). In patients with renal impairment (CrCl <30 mL/min), half-life extends to approximately 20–30 hours, requiring dose adjustment.
Approximately 2 hours in patients with normal renal function; prolonged to 3-5 hours in mild-moderate renal impairment and >20 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (unchanged); ~88% excreted in urine within 24 hours. Biliary/fecal elimination is negligible (<1% as metabolites).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic